MedTrace Logo

Cytoxan, Epirubicin and Capecitabine in Women With Breast Cancer

NCT00146588 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2015-03-24

No results posted yet for this study

Summary

The purpose of this study is to find out what effects (good and bad) a combination of cytoxan, epirubicin, and capecitabine have on women with Stage II/II/IIIA breast cancer.

Conditions

  • Breast Cancer
  • Stage I Breast Cancer
  • Stage II Breast Cancer
  • Stage IIIA Breast Cancer

Interventions

DRUG

Cyclophosphamide

Intravenously on day 1 of each 21-day treatment cycle for 12-18 weeks depending upon response.

DRUG

Epirubicin

Intravenously on day 1 of each 21-day treatment cycle for 12-18 weeks depending upon response.

DRUG

Capecitabine

Given orally on days 4-17 of each 21-day treatment cycle for 12-18 weeks depending upon response.

Sponsors & Collaborators

Principal Investigators

  • Craig Bunnell, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-04-30
Primary Completion
2004-12-31
Completion
2004-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00146588 on ClinicalTrials.gov